Neeraj Agarwal, MD

Articles

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

November 21st 2023

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

November 21st 2023

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Imaging and Staging Considerations in Renal Cell Carcinoma

November 14th 2023

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Dr Agarwal on the Benefit of PARP Inhibitors vs Chemotherapy in mCRPC

August 28th 2023

Neeraj Agarwal, MD, discusses the benefit of PARP inhibitors compared with chemotherapy in patients with metastatic castration-resistant prostate cancer.

Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC

July 26th 2023

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer

July 10th 2023

Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.

Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC

July 6th 2023

Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Dr. Agarwal on the Efficacy of Talazoparib Plus Enzalutamide in First-line mCRPC

February 17th 2023

Neeraj Agarwal, MD, discusses the efficacy of talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

October 6th 2021

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Dr. Agarwal on the Design of the AMPLITUDE Trial in mCSPC

September 24th 2021

Neeraj Agarwal, MD, discusses the design of the ongoing phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

August 24th 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Dr. Agarwal on the Significance of the LATITUDE Trial in Metastatic CSPC

February 2nd 2021

Neeraj Agarwal, MD, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate in patients with metastatic castration-sensitive prostate cancer.

Dr. Agarwal on Remaining Challenges With Abiraterone in mCSPC

December 21st 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on Remaining Challenges in mCSPC

December 11th 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on Unmet Needs in mHSPC

December 1st 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC

August 4th 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC

July 29th 2020

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Agarwal on Cohort 6 Results From the COSMIC-021 Trial in mCRPC

June 29th 2020

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.